IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype
IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype
复制标题
DOI：
10.1016/j.humpath.2009.05.005
复制
发表时间：
2009-11-01
期刊：
影响因子：
3.3
通讯作者：
Khan, Ashraf
中科院分区：
文献类型：
--
作者：
Walter, Otto;Prasad, Manju;Khan, Ashraf
IMP 3是一种癌胚蛋白，是胰岛素样生长因子-II（IGF-II）mRNA结合蛋白家族的成员。它作为一种新的生物标志物在肺，胰腺，肾和宫颈腺癌的相关性最近被发现。然而，其在乳腺癌发生和肿瘤进展中的作用尚未确定。基底细胞样癌最初通过基因表达谱鉴定。它占所有乳腺癌的15%至30%。这些肿瘤表达基底上皮细胞标志物，包括细胞角蛋白5，但缺乏雌激素受体、孕酮受体和人表皮生长因子受体2（HER 2）的表达，因此，通常被称为三阴性乳腺癌。已发现它们与更差的总体和无病生存期相关。在这项回顾性研究中，我们检测了IMP3在乳腺浸润性导管癌中的表达，并将其表达与形态学和生物学预后因素相关联。研究组包括138例浸润性导管癌，从1997年至2006年的10年期间的手术病理档案检索。所有138例患者的生存数据和临床分期均可用。从病理报告中获得肿瘤特征，包括大小、分级、淋巴管浸润、坏死、淋巴结转移、雌激素受体、孕激素受体和HER 2状态。使用抗IMP 3和CK 5/6的小鼠单克隆抗体对福尔马林固定的石蜡包埋组织进行免疫组织化学。在138例乳腺癌病例中，IMP3表达见于45例（33%）。25例IMP 3+病例为三阴性。我们发现IMP3表达与高级别（P = 0.001）、坏死（P
IMP3, an oncofetal protein, is a member of the insulin-like growth factor-II (IGF-II) mRNA-binding protein family. Its relevance as a novel biomarker in lung, pancreatic, renal, and cervical adenocarcinoma was recently revealed. However, its role in breast carcinogenesis and tumor progression is not yet established. Basal-like carcinoma was initially identified by gene expression profiling. It accounts for 15% to 30% of all breast cancers. These tumors express basal epithelia] markers including cytokeratin 5 but lack expression of the estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2), therefore, are often referred to as triple negative breast cancer. They have been found to be associated with a worse overall and disease-free Survival. In this retrospective study, we examined the IMP3 expression in invasive ductal carcinoma of the breast and correlated its expression with morphological and biologic prognostic factors. The study group comprised 138 cases of invasive ductal carcinoma retrieved from the surgical pathologic files for a 10-year period from 1997 to 2006. Survival data and clinical stage were available on all 138 patients. Tumor characteristics including size, grade, lymphovascular invasion, necrosis, lymph node metastasis, estrogen receptor, progesterone receptor, and HER2 status were obtained from pathologic reports. Immunohistochemistry was performed on formalin-fixed paraffin-embedded tissue using mouse monoclonal antibody against IMP3 and CK5/6. Of the 138 breast cancer cases, IMP3 expression was seen in 45 (33%). Twenty-five of the IMP3+ cases were triple negative. We found significant correlation between IMP3 expression and higher grade (P = .001), necrosis (P